Kazakhstan becomes the first country outside Russia to authorize Sputnik M vaccine for adolescents

Moscow, February 22, 2022 - The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) today announced that the Ministry of Health of the Republic of Kazakhstan has authorized the use of Sputnik M Russian vaccine for adolescents aged 12-17.

Thus Kazakhstan has become the first country outside Russia to authorize the use of Sputnik M.

In contrast with some international producers offering their vaccines in the same dosage for both adults and adolescents, the Gamaleya Center has developed Sputnik M specifically for adolescents.

Sputnik M is a two-shot vaccine against covid based on the same human adenoviral vectors platform, which is safe and has been widely studied for over 30 years. The only difference between Sputnik M and Sputnik V is a lower concentration of viral particles per dose: Sputnik M for adolescents has 5 times less concentration in comparison with the original Sputnik V in both shots.

Russian Ministry of Health registered Sputnik M on November 24, 2021 based on data from clinical trials confirming the high safety and immunogenicity profile of Sputnik M among adolescents. During the trials there were no serious adverse events registered following vaccination with Sputnik M. Current results are corresponding with those obtained during clinical trials and real-world data on vector vaccine against COVID 19 Gamaleya Center Sputnik V after vaccinating adults.

Sputnik V has been authorized in 71 country with total population of over 4 billion people. It induces stronger and longer lasting immune response against COVID (including the Omicron variant) than many other vaccines, which is further strengthened by Sputnik Light booster. A unique comparative study[1] conducted at Lazzaro Spallanzani National Institute for Infectious Diseases in Italy by a team of 12 Italian and 9 Russian scientists has shown that Sputnik V vaccine demonstrates more than 2 times higher titers of virus neutralizing antibodies to Omicron (B.1.1.529) variant than 2 doses of Pfizer vaccine (2.1 times higher in total and 2.6 times higher 3 months after vaccination).

The study was conducted in the equal laboratory conditions on comparable sera samples from individuals vaccinated with registered vaccine coronavirus RDIF Sputnik V and Pfizer with a similar level of IgG antibodies and virus neutralizing activity (VNA) against Wuhan variant. Sputnik V showed significantly smaller (2.6 times) reduction of virus neutralizing activity against Omicron as compared to reference Wuhan variant than Pfizer vaccine (8.1-fold reduction for Sputnik V in contrast to 21.4-fold reduction for Pfizer vaccine).

Based on the data collected by the Spallanzani Institute and results of Gamaleya Center’s studies Sputnik V provides for strong immune response against Omicron, which is further strengthened by boosting with one-shot Sputnik Light vaccine (the first component of Sputnik V).


Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 100 projects with foreign partners totaling over RUB2.1 tn and covering almost all of Russia’s regions. RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries that total more than $40 bn. Further information can be found at

For additional information contact:

Alexey Urazov
Russian Direct Investment Fund
Director for External Communications

Mobile: +7 915 312 76 65
E-mail: [email protected]

Andrew Leach / Maria Shiryaevskaya
Hudson Sandler

Tel: +44 (0) 20 7796 4133


Message has been successfully sent!

Thank you!
You have been subscribed